Beigene Stock Performance
| ONC Stock | 350.00 13.84 4.12% |
On a scale of 0 to 100, BeiGene holds a performance score of 6. The firm shows a Beta (market volatility) of 0.73, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BeiGene's returns are expected to increase less than the market. However, during the bear market, the loss of holding BeiGene is expected to be smaller as well. Please check BeiGene's total risk alpha, expected short fall, market facilitation index, as well as the relationship between the value at risk and daily balance of power , to make a quick decision on whether BeiGene's price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BeiGene are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, BeiGene exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 4.12 | Five Day Return 2.62 | Year To Date Return 12.53 | Ten Year Return 1.1 K | All Time Return 1.1 K |
1 | US Stock Market Today SP 500 Futures Rise as Rate Cut Bets Strengthen | 11/13/2025 |
2 | Disposition of 400 shares by John Oyler of BeiGene, at 327.78 subject to Rule 16b-3 | 11/24/2025 |
3 | Will FDA Priority Review for Sonrotoclax Transform BeOne Medicines Strategic Narrative | 12/02/2025 |
4 | Disposition of 332 shares by Chan Lee of BeiGene, at 318.28 subject to Rule 16b-3 | 12/10/2025 |
5 | Head to Head Contrast Relmada Therapeutics BeOne Medicines | 12/15/2025 |
6 | Disposition of tradable shares by John Oyler of BeiGene at 305.24 subject to Rule 16b-3 | 12/16/2025 |
7 | BeOne Medicines CEO John Oyler Sells 24,369 Shares | 12/17/2025 |
8 | BeOne Medicines Ltd. Sponsored ADR ONC Shares Bought by Voya Investment Management LLC | 12/26/2025 |
9 | BeOne Medicines Ltd. Sponsored ADR Given Average Rating of Moderate Buy by Brokerages | 01/06/2026 |
10 | Is the Options Market Predicting a Spike in BeOne Medicines Stock | 01/07/2026 |
11 | BeOne Medicines Earnings Momentum Spurs Valuation Debate And Analyst Optimism | 01/22/2026 |
| Begin Period Cash Flow | 3.2 B | |
| Total Cashflows From Investing Activities | -548.4 M |
BeiGene Relative Risk vs. Return Landscape
If you would invest 31,048 in BeiGene on October 31, 2025 and sell it today you would earn a total of 3,952 from holding BeiGene or generate 12.73% return on investment over 90 days. BeiGene is generating 0.2299% of daily returns assuming volatility of 2.6246% on return distribution over 90 days investment horizon. In other words, 23% of stocks are less volatile than BeiGene, and above 96% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
BeiGene Target Price Odds to finish over Current Price
The tendency of BeiGene Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 350.00 | 90 days | 350.00 | about 12.35 |
Based on a normal probability distribution, the odds of BeiGene to move above the current price in 90 days from now is about 12.35 (This BeiGene probability density function shows the probability of BeiGene Stock to fall within a particular range of prices over 90 days) .
Considering the 90-day investment horizon BeiGene has a beta of 0.73. This indicates as returns on the market go up, BeiGene average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding BeiGene will be expected to be much smaller as well. Additionally BeiGene has an alpha of 0.158, implying that it can generate a 0.16 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). BeiGene Price Density |
| Price |
Predictive Modules for BeiGene
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BeiGene. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BeiGene Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BeiGene is not an exception. The market had few large corrections towards the BeiGene's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold BeiGene, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BeiGene within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.16 | |
β | Beta against Dow Jones | 0.73 | |
σ | Overall volatility | 18.13 | |
Ir | Information ratio | 0.06 |
BeiGene Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BeiGene for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BeiGene can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the last year's revenue of 3.81 B. Reported Net Loss for the year was (644.79 M) with profit before taxes, overhead, and interest of 4.29 B. | |
| BeiGene generates negative cash flow from operations | |
| BeiGene has a poor financial position based on the latest SEC disclosures | |
| About 17.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from simplywall.st: BeOne Medicines Earnings Momentum Spurs Valuation Debate And Analyst Optimism |
BeiGene Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of BeiGene Stock often depends not only on the future outlook of the current and potential BeiGene's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BeiGene's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 105.3 M | |
| Cash And Short Term Investments | 2.6 B |
BeiGene Fundamentals Growth
BeiGene Stock prices reflect investors' perceptions of the future prospects and financial health of BeiGene, and BeiGene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BeiGene Stock performance.
| Return On Equity | 0.0181 | ||||
| Return On Asset | 0.0169 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 37.46 B | ||||
| Shares Outstanding | 101.81 M | ||||
| Price To Book | 9.38 X | ||||
| Price To Sales | 7.79 X | ||||
| Revenue | 3.81 B | ||||
| Gross Profit | 4.29 B | ||||
| EBITDA | (396.44 M) | ||||
| Net Income | (644.79 M) | ||||
| Total Debt | 1.08 B | ||||
| Book Value Per Share | 37.33 X | ||||
| Cash Flow From Operations | (140.63 M) | ||||
| Earnings Per Share | 0.53 X | ||||
| Market Capitalization | 38.73 B | ||||
| Total Asset | 5.92 B | ||||
| Retained Earnings | (8.61 B) | ||||
| Working Capital | 1.78 B | ||||
About BeiGene Performance
By analyzing BeiGene's fundamental ratios, stakeholders can gain valuable insights into BeiGene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BeiGene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BeiGene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 273.70 | 165.79 | |
| Return On Tangible Assets | (0.10) | (0.11) | |
| Return On Capital Employed | (0.18) | (0.19) | |
| Return On Assets | (0.10) | (0.10) | |
| Return On Equity | (0.22) | (0.23) |
Things to note about BeiGene performance evaluation
Checking the ongoing alerts about BeiGene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BeiGene help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the last year's revenue of 3.81 B. Reported Net Loss for the year was (644.79 M) with profit before taxes, overhead, and interest of 4.29 B. | |
| BeiGene generates negative cash flow from operations | |
| BeiGene has a poor financial position based on the latest SEC disclosures | |
| About 17.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from simplywall.st: BeOne Medicines Earnings Momentum Spurs Valuation Debate And Analyst Optimism |
- Analyzing BeiGene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BeiGene's stock is overvalued or undervalued compared to its peers.
- Examining BeiGene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BeiGene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BeiGene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BeiGene's stock. These opinions can provide insight into BeiGene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |